{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:41:41Z","timestamp":1780537301958,"version":"3.54.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"am","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clgc.2023.09.003","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T02:01:52Z","timestamp":1695002512000},"page":"e122-e127.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7383-5322","authenticated-orcid":false,"given":"Leandro","family":"Blas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigehiro","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Nagakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-9930","authenticated-orcid":false,"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.09.003_bib0001","first-page":"1","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"0","author":"Hyuna Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"23","key":"10.1016\/j.clgc.2023.09.003_bib0002","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMra043172","article-title":"Renal-cell carcinoma","volume":"353","author":"Cohen","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clgc.2023.09.003_bib0003","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European Association of Urology Guidelines on renal cell carcinoma: the 2022 update","volume":"82","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.clgc.2023.09.003_bib0004","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clgc.2023.09.003_bib0005","doi-asserted-by":"crossref","first-page":"e000891","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2023.09.003_bib0006","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2023.09.003_bib0007","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2023.09.003_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.clgc.2023.09.003_bib0009","unstructured":"United States Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. Available at: \u200bhttps:\/\/www.fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"10.1016\/j.clgc.2023.09.003_bib0010","unstructured":"Medical Dictionary for Regulatory Activities. Available at: https:\/\/www.meddra.org\/."},{"issue":"5","key":"10.1016\/j.clgc.2023.09.003_bib0011","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.euo.2021.03.001","article-title":"First-line immunotherapy-based combinations for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"4","author":"Quhal","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2023.09.003_bib0012","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.eururo.2021.03.016","article-title":"A living, interactive systematic review and network meta-analysis of first-line treatment of metastatic renal cell carcinoma","volume":"80","author":"Bin","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.09.003_bib0013","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.clgc.2023.09.003_bib0014","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JU.0000000000002252","article-title":"Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"207","author":"Nocera","year":"2022","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:38:10Z","timestamp":1761565090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S1558767323002057"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.09.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}